SOURCE: Celmatix


October 17, 2014 09:26 ET

Celmatix Appoints David L. Stern to Chief Commercial Officer

NEW YORK, NY--(Marketwired - Oct 17, 2014) - Celmatix, a privately held personalized medicine company focused on maximizing lifelong fertility, today announced the appointment of David L. Stern to Chief Commercial Officer. Mr. Stern will be responsible for developing and executing the company's go-to-market strategies, including for Polaris, the world's first analytics platform that allows fertility doctors to optimize treatment recommendations for individuals based on their personal metrics.

A seasoned executive in the fertility space, Mr. Stern joins Celmatix from OvaScience, where he served as Executive Vice President of Global Commercial Operations. Before that, he spent ten years at Merck Serono, most recently as Senior Vice President and Head of the Global Business Franchise for Fertility, where he was responsible for the strategic development and growth of the fertility portfolio worldwide.

"David is a strong addition to our leadership team as we bring to market Polaris and other innovative products we are developing based on our novel research discoveries," said Dr. Piraye Yurttas Beim, Founder and CEO, of Celmatix. "His expertise in strategic development and knowledge of the fertility industry make him an ideal CCO for Celmatix."

"With more than 20 years experience in the field of fertility, I believe Polaris and Celmatix are meeting an unmet need to help patients better understand what is the best personalized path to parenthood." said David L. Stern. "I'm excited to leverage my experience and existing relationships to successfully launch Polaris."

Another related position David Stern has held previously is Director, Reproductive Marketing, at Organon USA where he worked closely with fertility clinics in sales and marketing roles. Mr. Stern graduated from Brandeis University and received his M.B.A. from Babson College.

About Celmatix, Inc.
Founded in 2009, Celmatix is a New York City-based personalized medicine company focused on maximizing lifelong fertility. By leveraging innovations in genomics, data science, and information technology, Celmatix is creating products that help personalize the treatment for infertility and fertility planning. Celmatix's key research discoveries include powerful predictive models that can calculate personalized chances for success with different treatment options across multiple cycles and the identification of Fertilome™DNA, the regions of the human genome that are most likely to influence a woman's fertility potential. For more information, visit

Contact Information